You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 131 No. 9, September 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence: Vignettes
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Metronidazole for Eosinophilic Pustular Folliculitis in Human Immunodeficiency Virus Type 1-Positive Patients

COL Smith, MC; CDR Henry G. Skelton, MC; CDR Josef Yeager, MC; Nancy Ruiz, MD; Kenneth F. Wagner, DO
USA Washington, DC; USN Department of Dermatopathology Armed Forces Institute of Pathology Washington, DC 20306; USN; Bethesda, Md

Arch Dermatol. 1995;131(9):1089-1091.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Eosinophilic pustular folliculitis (EPF) of Ofuji presents as coalescing papulopustular plaques with central clearing and postinflammatory hyperpigmentation, occurring in otherwise healthy adults.1 In patients who are human immunodeficiency virus type 1-positive (HIV+), EPF occurs as pruritic, discrete erythematous urticarial follicular papules, usually distributed over the head and neck areas, sometimes with extension to the proximal aspect of the upper extremities and the upper aspect of the trunk, and may be a separate disorder.2 In previous reports and in our patients this condition tends to occur in late-stage disease, Walter Reed stages 5 and 6, with CD4 counts of less than 0.25 to 0.30x109/L.2 The eruption tends to be chronic and resistant to therapy, and although the majority of our patients have moderate-to-severe pruritus, they do not develop sepsis or other systemic symptoms that are directly related to EPF.

Demodex, Tinea, Pityrosporum, and Staphylococcus aureus have . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.